Eton Pharmaceuticals Inc.
13.28
-0.14 (-1.04%)
At close: Jan 15, 2025, 9:33 AM
undefined%
Bid 13.16
Market Cap 353.71M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.21
PE Ratio (ttm) -63.24
Forward PE n/a
Analyst Strong Buy
Ask 13.66
Volume 4,841
Avg. Volume (20D) 227,237
Open 13.55
Previous Close 13.42
Day's Range 13.28 - 13.55
52-Week Range 3.03 - 15.00
Beta undefined

About ETON

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezip...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2018
Employees 30
Stock Exchange NASDAQ
Ticker Symbol ETON

Analyst Forecast

According to 3 analyst ratings, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $18, which is an increase of 35.54% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Eton Pharmaceuticals Inc. is scheduled to release its earnings on Mar 13, 2025, during market hours.
Analysts project revenue of $10.55M, reflecting a 44.26% YoY growth and earnings per share of 0, making a -100.00% decrease YoY.
2 months ago · Source
+15.59%
Eton Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
3 months ago · Source
+16.33%
Eton Pharmaceuticals shares are trading higher after the company announced they entered into an asset purchase agreement to acquire Increlex from Ipsen.